Posterior (Bilateral Parieto-occipital) Cortical Atrophy: A Case Study

ArticleinNoropsikiyatri Arsivi 46(4) · January 2009with181 Reads
Source: DOAJ
Scientific Background: Primary degenerative dementia can show different features in the early stages and can start with asymmetric or symmetric focal degeneration. Posterior cortical atrophy is a rare progressive dementia syndrome which can be evaluated, using neuropsychological tests and neuroimaging techniques, along with clinical features. Definitive diagnosis is made histopathologically.Objective: To discuss the clinical features of a case with posterior cortical atrophy, characterized by progressive visuospatial disorder, and the differential diagnosis, under the light of related literature.Results: Neurocognitive assessment revealed a serious visuospatial and constructional disturbance as well as facial recognition defects, dressing apraxia and agraphia, and a mild memory and verbal fluency impairment. Cranial MRI demonstrated bilateral parieto-occipital atrophy, and the SPECT investigation showed decreased perfusion in the right temporoparieto occipital region compared to the left hemisphere. Routine and other laboratory investigations were normal. Conclusion: The patient was started on memantine with a daily dose of 20 mg, twice a day. After four months, he became temporarily able to drive and park his tractor, but, the symptoms progressed later. (Archives of Neuropsychiatry 2009; 46: 192-6)
  • [Show abstract] [Hide abstract] ABSTRACT: There is an enormous market and great rants related with psychotropic medication in all over the world, with even some ethical violation going on, between firms and doctors. Although governments are trying to take these under control, with the aid of some statistical deceiving in research and publications, the psychiatrists are trying to be hoodwinked. We now have plenty of drugs and naturally, there is a great competition in the market. This situation created a de facto relation type: Manufacturer + the prescriber + the seller (pharmacist etc.) + the payer + the consumer! When the magnitude of budget and competition is considered, both firms, and the doctors cooperating with them are under great ethical responsibilities: a) drug research, b) publications, and c) promotions! The "explosion" of the generics makes the situation even more complicated. In this article we tried to scan the latest and reliable publications, and we tried to introduce important updates which will falsify our recent or conventional knowledge and of course we tried to point out our colleagues to be more discrete and cautious.
    Article · Jan 2011